by distinctive changes, such as ballooning and multinucleated keratocytes in measles and keratocytes with steel-grey nuclei with margination of nucleoplasm in infections by herpesviruses [11] [12] . Often, however, there are no such distinguishing features. Common patterns of viral exanthemata include a superficial perivascular infiltrate of lymphocytes without associated epidermal changes, a superficial vacuolar interface dermatitis, sometimes associated with eosinophils and neutrophils, a lichenoid dermatitis, and a mild spongiotic dermatitis. All those patterns may also be encountered in drug eruptions [10] .
Despite those limitations, drug eruptions can usually be diagnosed with confidence on the basis of histopathologic changes alone. It is common practice in laboratories of dermatopathology to examine sections of biopsy specimens before obtaining any clinical information. If this is done, and the presumptive diagnosis of a drug eruption is rendered, it is our experience that the latter is usually corroborated by the clinical diagnosis of the referring physician. All histopathologic diagnoses must be submitted to critical review in the context of additional information, such as clinical findings, clinical history, and laboratory data. This does not distinguish drug eruptions from any other skin disease, and the reliability of histopathologic diagnosis of a drug eruption is not smaller than that of diseases for which biopsy is recommended without reservation, be it lichen planus, lupus erythematosus, or granuloma annulare.
In the following, we wish to discuss criteria that aid in recognition of drug eruptions in general, describe common patterns of drug eruptions, and discuss the differential diagnosis of those patterns. The statements made are based on personal experience of many years, on a review of the literature, and on systematic analysis of histopathologic findings in 60 cases of maculopapular drug eruption in which the eliciting drugs were known and the eruption cleared following cessation of them. In that study, cases diagnosed clinically In 1997, Ackerman emphasized that "drugs can elicit any of the nine basic patterns of inflammatory diseases in the skin, and none of those patterns is specific for a drug eruption.
There is but one exception, to date, to the precept that drug eruptions cannot be diagnosed with specificity through the microscope, namely, fixed drug eruption" [1] .
In more than a decade following that sobering assessment of the import of histopathological analysis for the diagnosis of drug eruptions, only little progress has been made. For some differential diagnoses, criteria have been set forth to facilitate distinction of drug eruptions from other inflammatory skin diseases, e.g., lichenoid drug eruption from lichen planus, psoriasiform drug eruption from psoriasis vulgaris, and granulomatous drug eruption from granuloma annulare.
In a recent review of histopathologic patterns of cutaneous drug eruptions, one finding indicative of drug eruptions in general has been noted, namely, combination of different patterns in a single specimen. Another finding mentioned as "a diagnostic clue" to drug eruptions was presence of eosinophils, but the authors emphasized that "one must be cautious not to consider them the panacea of histologic diagnosis for a drug reaction as their presence does not make a drug reaction the correct diagnosis. Conversely, the absence of eosinophils does not rule out a drug eruption. In other words, they may or may not be present in these reactions" [2] .
The vagueness of histopathologic descriptions of drug eruptions, and the caution exercised in interpretation of them, has created the impression that biopsy of drug eruptions has little value. Current textbooks of dermatology emphasize that, in reactions to drugs, "the histological changes are no more distinctive than are the clinical features," the only exceptions being "vegetating iododermas and bromodermas, certain lichenoid eruptions and fixed drug eruptions," in which "the histological changes … are not pathognomonic, but are sufficiently characteristic to be of importance in differential diagnosis" [3] . No such importance is attributed to histopathologic study of morbilliform drug eruptions, which have been estimated to account for 95% of all drug eruptions [4] . The latter are said to show only "non-specific lymphohistiocytic infiltrates in perivascular arrangement.
For that reason, histopathologic examination can contribute only little to diagnosis and differential diagnosis" [5] . As a consequence, it has been stated unequivocally that "biopsy of morbilliform eruptions is not recommended" [6] .
In our view, those conclusions are wrong and potentially harmful, as they may lead to incorrect diagnoses and mismanagement of patients. It is true that histopathologic diagnosis of drug eruptions may be difficult, may remain equivocal, and require clinico-pathologic correlation, but this is true for all diseases. Compared to other inflammatory diseases of the skin, histopathologic diagnosis of drug eruptions is impeded by the fact that drugs may not only cause eruptions as drug-induced erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, as well as lichenoid and bullous drug eruptions were excluded. results of that study are being published separately [13] . For this review, we re-examined biopsy specimens of 300 consecutive cases seen in our laboratory in which the diagnosis of a drug eruption of any kind was given both, histopathologically and clinically, but in which data concerning the eliciting drug and follow-up were available for only a minority of patients. The purpose of that endeavor was to assess the relative frequency of different histopathologic patterns of drug eruptions in the routine material of a laboratory of dermatopathology. Findings of that survey are summarized in Table 1 .
general criteria
Several findings are typical of drug eruptions in general. Some of them may appear banal. Nevertheless, when encountered in association with a particular pattern, they may help to rule out other diseases associated with that pattern. These findings include:
signs of acuteness
Drug eruptions, as their name indicates, are usually acute, eruptive diseases that appear suddenly and progress rapidly in both, extension and intensity. As a consequence, they are usually biopsied early in their course. Histopathologic evidence of an eruptive disease biopsied early in its course includes
• a normal basket-woven cornified layer despite spongiosis or hydrops of keratocytes in the basal or spinous zone (the reason being that the interval of time between onset of the eruption and biopsy of it is too small to permit alterations in the lower epidermis to affect to stratum corneum),
• edema of the papillary dermis,
• angiectases of capillaries and venules in the superficial dermis,
• many neutrophils in the lumina of dilated venules,
• extravasation of erythrocytes.
By contrast, signs of chronicity militate against a drug eruption, namely,
• marked epithelial hyperplasia,
• marked hyperkeratosis,
• coarse collagen bundles in elongated dermal papillae,
• fibrosis of the papillary and superficial reticular dermis,
• numerous melanophages or siderophages in the superficial dermis. Superficial  10  0  28  55  26  11  54  18  4  0  0   Superficial  and deep   2  12  10  28  10  7  8  1  2  12  2   Perivascular  11  0  5  12  0  0  6  0  0  0  0   Interstitial  1  12  33  71  36  18  56  19  6  12  2   Vacuolar   +  0  0  0  83  28  17  41  11  3  6  1   ++  0  0  38  0  8  1  0  2  3  0  0   Spongiosis   +  0  0  38  44  16  18  56  12  2  3  0   ++  0  0  0  0  0  0  6  7  0  0  0   Necrotic  keratinocytes   +  0  0  4  62  22  11  10  7  5  0  0   ++  0  0  34  0  13  4  0  1  1  0  0   Eosinophils   +  0  8  20  51  17  13  45  13  6  10  0   ++  0  4  12  18  2  4  13  6  0  0  2   Neutrophils   +  0  10  18  40  4  6  33  0  4  2  0   ++  0  2  8  0  0  1  3  19  0  0  2 
Neutrophils in vessels
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Of course, drug eruptions may also be chronic and may be biopsied after many months. (Figure 1 a, b ).
Vacuolar interface dermatitis
The most common histopathologic pattern of drug eruptions is a vacuolar interface dermatitis. The extent of interface changes varies greatly, from extensive vacuolar alteration at the dermo-epidermal junction and many necrotic keratocytes at all levels of the epidermis, as in most cases of fixed drug eruption and toxic epidermal necrolysis, to focal and very subtle changes. The latter may not be apparent immediately.
When a drug eruption is suspected, it is worthwhile to screen all sections of the biopsy specimen for evidence of a subtle vacuolar interface dermatitis.
Presence of neutrophils and eosinophils
Drug eruptions, like many other inflammatory diseases, are often associated with an infiltrate of eosinophils and/or neutrophils. In a recent study of morbilliform drug eruptions, eosinophils were found in 50% and neutrophils in 36% of cases [18] . In our study of maculopapular drug eruptions in which the eliciting agents were known, the numbers were higher, namely, 60% for eosinophils and 50% for neutrophils. In brief, eosinophils and/or neutrophils are present in the majority of drug eruptions. Eosinophils are more common, but because they are seen in such a wide variety of diseases, they are less distinctive for drug eruptions. An infiltrate of neutrophils is rarer but of greater diagnostic import. 
several histopathologic patterns in a biopsy specimen
Drug eruptions may present themselves with different histopathologic patterns. Each of those patterns may be caused by a variety of inflammatory skin diseases. A combination of two or more patterns in a single biopsy specimen, however, favors a drug eruption.
As mentioned above, the most common pattern of drug eruptions is an interface dermatitis which is usually also seen when patterns are combined. regardless of the pat- 
other clues to diagnosis of a drug eruption
Drug eruptions usually affect trunk and extremities. Palms and soles are involved only rarely, and if they are, there are usually also lesions at other sites that are selected for biopsy.
As a consequence, drug eruptions, with the exception of fixed drug eruption, are biopsied rarely on palms and soles.
The same is true for the face and scalp. Hence, when one sees a biopsy specimen from face, scalp, or palmar and plantar surfaces, a drug eruption is unlikely.
Drug eruptions are most common in elderly patients. 
Common patterns and differential diagnoses lymphocytic dermatitis without epidermal changes
This is the least distinctive pattern of a drug eruption. It is 
Vacuolar interface dermatitis
Vacuolar interface dermatitis is the most common pattern of drug eruptions. In a recent study of morbilliform drug eruptions, interface changes were described in 53% of cases [18] .
In our study of maculopapular drug eruptions, subtle vacuolar changes at the dermo-epidermal junction were noticed in 58 of 60 cases (97%), and of the 300 consecutive cases, 141 (47%) were classified as vacuolar interface dermatitis, although subtle vacuolar changes at the junction were also present in cases in which another pattern predominated. 
a) severe vacuolar interface dermatitis
This pattern was encountered in 38 of 300 cases (13%), 13
of which were diagnosed clinically as fixed drug eruption.
The latter did not differ substantially from other cases of this group. In 26 cases, numerous eosinophils and neutrophils were present in the infiltrate, and in 10 cases, at least some eosinophils and/or neutrophils could be detected. Only four cases were associated with a wholly lymphocytic infiltrate.
Areas of confluent epidermal necrosis were observed in nine cases, including four cases of fixed drug eruption. In 10 cases (including five of fixed drug eruption), the infiltrate extended into the lower half of the dermis.
The differential diagnosis of these cases includes postherpetic erythema multiforme. The epidermal changes are indistinguishable. In general, the infiltrate in post-herpetic erythema multiforme is more perivascular and restricted to the superficial dermis, but involvement of the interstitium and the lower dermis may occur. In the vast majority of cases of post-herpetic erythema multiforme, the infiltrate is wholly lymphocytic. In the literature, eosinophils have been reported in erythema multiforme but, with rare exceptions [21] , no clear distinction was made between post-herpetic and druginduced cases [22] [23] . When those cases were distinguished, eosinophils were found to be more common in drug-induced erythema multiforme [24] [25] . This corresponds to our own experience. For the purpose of this study, we re-examined biopsy specimens of five patients with recurrent post-her- Other diseases entering into the differential diagnosis of drug eruptions with severe vacuolar interface changes are acute cases of pityriasis lichenoides and lupus erythematosus.
In the latter conditions, the infiltrate is usually superficial and deep, whereas it is only superficial in the majority of DEs with severe interface changes. In pityriasis lichenoides, the infiltrate is often wedge-shaped, a pattern not observed in drug eruptions, and usually consists of lymphocytes only, whereas most drug eruptions are associated with neutrophils and [26] [27] [28] , their presence has led repeatedly to misdiagnosis as a drug eruption, thereby delaying treatment of graft-versus-host disease [29] . As a consequence, it has been recommended not to perform skin biopsies in settings with high probability of acute graft-versus-host disease, such as following allogenic stem cell transplantation [30] . However, in addition to eosinophils that are of limited diagnostic value, other findings may serve to distinguish a drug eruption from acute graft-versus-host disease, including deep extension of the infiltrate and presence of neutrophils. Extension of the infiltrate into the deep dermis is observed in only a minority of drug eruptions, but neutrophils are commonly found and were numerous in more than half of our drug eruptions associated with severe interface changes, sometimes exceeding eosinophils in number. By contrast, in one study of acute graft-versus-host disease, not a single neutrophil was observed in 98 biopsy specimens [26] .
b) mild vacuolar interface dermatitis
A mild vacuolar interface dermatitis with only subtle vacuolar changes at the dermo-epidermal junction and few, if any, necrotic keratocytes is the most common pattern of drug eruptions. In our study of 300 consecutive drug eruptions, it was observed in 83 cases (28%). As mentioned previously, the constellation of mild vacuolar interface changes and a sparse superficial perivascular and interstitial infiltrate of lymphocytes, eosinophils, and neutrophils is virtually diagnostic of a drug eruption (Figure 5 a, b) .
The differential diagnosis of drug eruptions with mild vacuolar interface changes includes diseases normally associated with a more pronounced interface dermatitis, such as lupus erythematosus and acute graft-versus-host disease, but also diseases that are never associated with severe interface changes, including viral exanthemata and some autoimmune bullous diseases, especially the urticarial stage of bullous pemphigoid. Because the latter may also be associated with a superficial perivascular and interstitial infiltrate of eosinophils and neutrophils, distinction of it from a drug eruption may be particularly challenging. A clue to diagnosis of bullous pemphigoid is presence, and sometimes cluster- 
spongiotic dermatitis
Drug eruptions commonly present themselves as a spongiotic dermatitis. We found a spongiotic dermatitis in 62 of 300 consecutive drug eruptions (21%), and some spongiosis was also present in many other cases in which it was not the predominant pattern. In our study of maculopapular drug eruptions in which the eliciting agents were known, 58 of 60 cases (97%) were associated with at least subtle spongiosis [11] . Most commonly, spongiosis is mild and confined to the lower half of the epidermis. Spongiotic vesicles were seen in less than half of the cases classified as spongiotic dermatitis.
Those vesicles were usually small and confined to one or two foci, a pattern observed in 20 of 62 cases (32%). Marked spongiosis across a broad front with large confluent vesicles was seen in only 6 cases (10%), all of which were associated with at least some eosinophils and neutrophils in the epidermis.
Spongiotic drug eruptions must be distinguished from other spongiotic dermatitides, especially pityriasis rosea, erythema annulare centrifugum, and contact and nummular dermatitis. Unlike drug eruptions, those diseases are rarely 
Pustular dermatitis
Neutrophils in the epidermis are commonly observed in drug eruptions. In our study of maculopapular drug eruptions in which the eliciting agents were known, 19 of 60 cases (32%)
were associated with at least some neutrophils in the epider- The differential diagnosis of pustular drug eruptions includes pustular psoriasis, deficiency disorders such as necrolytic migratory erythema and acrodermatitis enteropathica, and pemphigus, especially IgA pemphigus. In pemphigus, the infiltrate tends to be relatively evenly distributed.
In the dermis, it is usually restricted to the upper half and does not show significant perivascular accentuation. In the epidermis, neutrophils may be dispersed evenly across a broad front in concert with scant spongiosis [42] . By contrast, the infiltrate in drug eruptions is often accentuated around blood vessels and may be deep as well as superficial.
In the epidermis, neutrophils are not scattered broadly but usually aggregated in discrete foci. Evidently, signs of acantholysis favor pemphigus and militate against a drug eruption, although some acantholytic cells may also be found in pustules of drug eruptions. In cases of doubt, this differential diagnoses can be resolved easily by immunofluorescence studies.
Intra-or subcorneal abscesses in deficiency disorders are usually elongated rather than discrete, as in most cases of pustular drug eruptions. When drug eruptions are associated with elongated abscesses, the infiltrate is usually very dense However, eosinophils tend to be sparse in number, whereas there are often abundant eosinophils in drug eruptions.
Moreover, unlike pustular drug eruptions, lesions of prurigo pigmentosa commonly exhibit nuclear dust [43] .
The most important differential diagnosis of pustular drug eruptions is pustular psoriasis. Pustular psoriasis is more difficult to distinguish from drug eruptions than other types of psoriasis because of lack of epidermal hyperplasia and common presence of some eosinophils. In drug eruptions, however, eosinophils are more numerous and may be seen in clusters, a finding militating strongly against psoriasis. In a recent comparison of acute generalized exanthematous pustulosis and pustular psoriasis, criteria with the highest distinguishing value in favor of the former diagnosis were eosinophils, especially when present within pustules, necrotic keratocytes, focal leukocytoclasia, and deep extension of the infiltrate [44] . Moreover, spongiosis in pustular drug eruptions has been claimed to be "usually mild, in contrast to that seen in pustular psoriasis." [2] subepidermal bullous dermatitis 
granulomatous dermatitis
Drug eruptions may be associated with granulomatous inflammation. We observed granulomas in 12 of 300 consecutive drug eruptions (4%). Two patterns of granulomatous inflammation could be distinguished. In five cases, there were one or few small, round to oval, sharply circumscribed granulomas in the upper dermis. In three of those cases, at least one granuloma was situated in close proximity to an eccrine duct, suggesting damage to the duct and leakage of sweat as a possible cause of granulomas. All five cases were associated with epidermal changes, either focal spongiosis (two cases), or foci of interface dermatitis (two cases), or both (one case). The associated epidermal changes distinguished those drug eruptions from the most important differential diagnosis, sarcoidosis (Figures 2 a, b) . Another clue to diagnosis of a drug eruption observed in two cases were neutrophils in the lumina of venules, a finding hardly ever observed in sarcoidosis.
The second pattern of granulomatous dermatitis was scatter of histiocytes among collagen bundles in one or more poorly circumscribed areas in the superficial and/or deep dermis. There also was a perivascular lymphocytic infiltrate.
Those changes resembled the interstitial type of granuloma annulare. Of seven cases with that pattern, two were indistinguishable from granuloma annulare. In both, a drug eruption could be diagnosed with confidence because of onset of lesions following administration of a new drug (captopril and allopurinol, respectively) and gradual resolution after cessation of it. In those two cases, numerous eosinophils were present, but the latter may also be seen in granuloma annulare.
The five other cases could be distinguished from granuloma annulare because of associated epidermal changes, namely, interface changes in four and spongiosis in one of them. Subtle signs of an interface dermatitis have been described as a histopathologic clue to diagnosis of a granuloma annularelike drug eruption [45] . In five of our seven cases of granuloma annulare-like drug eruption, eosinophils and neutrophils were sparse or absent. A clue to diagnosis of a drug eruption present in four of seven granuloma annulare-like lesions was presence of neutrophils in the lumina of venules.
leukocytoclastic vasculitis
In our study of 300 consecutive drug eruptions, two cases showed signs of leukocytoclastic vasculitis. In both, a clinical diagnosis of drug eruption had been given because of onset of lesions shortly after administration of a new drug. In one of those cases, the same type of eruption had occurred once before following administration of the same drug (azithromycin). Both cases showed stereotypic features of leukocytoclastic vasculitis, namely, fibrin in the walls of venules, extravasation of erythrocytes, and an inflammatory infiltrate composed of lymphocytes, neutrophils, and eosinophils in concert with nuclear dust. In both cases, there were more eosinophils than normally seen in leukocytoclastic vasculitis, including focal clusters of eosinophils. This is in concurrence with a recent study in which a significantly higher number of eosinophils was found in drug-induced than in non-druginduced cases of leukocytoclastic vasculitis. In that study, the course of drug-induced cases was found to be less severe, with lower incidence of extra-cutaneous involvement and faster resolution [46] . Although presence of many eosinophils does not exclude other causes of leukocytoclastic vasculitis, it may serve as a clue to causation by a drug.
Discussion
Adverse cutaneous reactions to drugs may occur in many different forms. So divergent are the patterns of drug eruptions that they cannot be considered variants of a single pathologic process. Evidently, the cytokines involved in eruptions presenting as a pustular, spongiotic, or severe interface derma- to attach individual cases to one of the categories of patterns.
This, however, is not only unavoidable, but irrelevant for the purpose of distinguishing drug-induced cutaneous eruptions from those not induced by a drug. For that purpose, it is helpful to consider the differential diagnosis of a given pattern and findings that allow drug eruptions to be recognized in that particular context. The categories of patterns discussed above do not encompass the entire spectrum of drug eruptions. For example, there were no examples of nodular dermatitis and panniculitis among our cases. Nevertheless, the vast majority of drug eruptions can be assigned to one of the aforementioned categories, and if general criteria for recognition of drug eruptions are observed, and the particular differential diagnoses considered, histopathologic diagnosis of a drug eruption can usually be made with confidence. As in all other inflammatory diseases, the histopathologic diagnosis must be substantiated by clinicopathologic correlation.
